Yeah, whatever, Yosid. I remember when you were touting Summit, and saying what a great value it was using your market cap analysis methodology. The reason why I made such a big deal about Visx's superior laser in the past is because of what is happening right now. Visx STAR became the laser of choice even before approval, and now is providing Visx with tremendous cash flow Summit can only dream about. Summit's inferior technology and flawed business model has resulted in their current low volume/barely breakeven situation.
However, now that Summit is approved for astigmatism, I expect Apex procedure volume to grow very nicely, putting Summit back in the black.
Anyone investing in this sector shouldn't avoid the main cash-generator, Visx. It's not going to stop for a long time, if ever. |
